Introduction {#S0001}
============

Sleep disorders are common in patients with chronic diseases, such as rheumatoid arthritis (RA). Poor sleep quality has been linked to pain, mood, fatigability, stress, and disease activity in the rheumatic disease population.[@CIT0001] Various primary sleep disorders have been observed in RA, including a high prevalence of obstructive sleep apnea (OSA),[@CIT0002] insomnia,[@CIT0003] and restless legs syndrome (RLS).[@CIT0004] Abbasi et al[@CIT0005] determined that the frequency of sleep disorders among 100 RA patients is 72%. More recently, Westhovens et al[@CIT0001] conducted a survey involving 305 patients and concluded that poor control of RA is associated with a reduction in sleep quality, which is likely explained by pain-related arousals.

The risk of OSA among RA patients is reported to be as high as 50%.[@CIT0002] In addition to the well-defined risk factors for OSA, patients with RA may have gross anatomic abnormalities that can cause upper-airway narrowing.[@CIT0006] Redlund-Johnell[@CIT0006] studied 400 patients with RA and found that 70% of those with severe arthritic temporomandibular joint (TMJ) destruction leading to acquired retrognathia experienced episodes of upper-airway obstruction. Hence, TMJ destruction has been observed as a potential risk for OSA in patients with RA.

A recent literature review addressing RLS in RA patients reported that RLS is a frequent comorbidity with prevalence rates of up to 30% and concluded that RLS is an underdiagnosed condition that can seriously impact sleep.[@CIT0004] In another study, chronic insomnia was assessed in a cross-sectional multicenter survey of 689 subjects with RA in Brazil. The results showed that elderly subjects with RA had a 1.6-fold increased risk of experiencing insomnia symptoms compared to subjects without RA.[@CIT0003] Moreover, Purabdollah et al[@CIT0007] studied the effects of variable sleep disorders on the quality of life in 210 patients with RA and concluded that sleep disorders and pain are associated with a poor quality of life in patients with RA.

Although the literature suggests that there may be a link between common sleep disorders and RA, but this relationship is still not well established. Furthermore, the effect of sleep disorders on the disease activity of RA remains undetermined. Therefore, the aims of the present study were to further determine the prevalence of common sleep disorders, namely, sleep disturbance, the risk of OSA, RLS, and insomnia, among patients with RA. In addition we investigated the effect of these sleep disorders on the disease activity and quality of life in patients with RA.

Patients and methods {#S0002}
====================

Subjects {#S0002-S2001}
--------

The study sample consisted of 101 patients who attended the rheumatology clinic at King Abdulaziz University Hospital, Jeddah, Saudi Arabia between October 2015 and May 2016. The inclusion criteria for subject enrollment were an age \>18 years; and diagnosis of RA according to the American Rheumatology Association (ARA 1987), indicating that at least four of the following seven criteria are required to establish the diagnosis of RA: 1) periarticular morning stiffness for 1 hr or longer; 2) at least three or more joints with arthritis documented by a physician; 3) involvement of proximal interphalangeal joints (PIP), metacarpophalangeal joints (MCP) or the wrist joints; 4) symmetrical distribution of arthritis; 5) presence of rheumatoid nodules; 6) positive rheumatoid factor (RF); and 7) marginal erosions or periarticular osteopenia in radiological studies.[@CIT0008] The first four criteria should be present for a minimum of 6 weeks.[@CIT0009] Ethical approval was obtained from the Ethical Committee of King Abdulaziz University Hospital (KAUH), Jeddah, with reference number 265--14. All patients agreed to participate in this study signed an informed consent.

Data collection {#S0002-S2002}
---------------

Physicians evaluated all patients using a structured questionnaire and a clinical examination. Furthermore, all questionnaires were translated to Arabic language versions to avoid misunderstandings by the patients. The collected information included sociodemographic characteristics, patient medical histories, Disease Activity Score (DAS28), Berlin questionnaire to assess the risk of OSA, Epworth Sleepiness Scale (ESS) to assess daytime sleepiness, Athens Insomnia Scale (AIS) to assess insomnia, International RLS Study Group (IRLSSG) score to diagnose RLS, and Health Assessment Questionnaire (HAQ) to assess the quality of life. The anthropometric measurements of all patients, including height, weight, body mass index (BMI), neck circumference and blood pressure, were recorded by nurses upon initial recruitment. Laboratory tests for different diseases affecting patient sleep or confirming RA and its assessment, including complete blood counts (CBCs), iron profile, calcium, vitamin D, vitamin B12, thyroid function test, diabetes check-up, renal function test, inflammatory markers \[erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)\] and rheumatoid-arthritis-specific antibodies (RF and anti-cyclic citrullinated peptide), were performed for all patients at the KAUH laboratory.

Instruments {#S0002-S2003}
-----------

### Disease Activity Score (DAS28) {#S0002-S2003-S3001}

The assessment of the RA disease activity was based on the DAS28 score system, which is a global summative and continuous score for disease activity assessment.[@CIT0009] Compared with other tools used for the assessment of disease activity, the DAS28 is one of the most reliable tools recommended by the American College of Rheumatology.[@CIT0009] The DAS28 assessment depends on clinical and biochemical factors and includes a measurement of the number of swollen and tender joints, acute phase reactant (ESR or CRP) and patient's global assessment of disease activity, which is scored from zero to 100 with higher scores indicating active disease.[@CIT0009] The ranges of DAS28 scores corresponding to high, moderate, and low disease activity and remission have been proposed. High disease activity corresponds to DAS28\>5.1, moderate disease activity corresponds to DAS28\>3.2 to 5.1, low disease activity corresponds to 2.6--3.2, and remission corresponds to \<2.6.[@CIT0010]

### Pittsburgh Sleep Quality Index (PSQI) {#S0002-S2003-S3002}

The PSQI is a standardized and valid scale developed to differentiate poor from good sleepers and evaluate the sleep quality in the previous month.[@CIT0011] The PSQI includes 19 self-rated questions. A global PSQI score was calculated by using the PSQI scoring database. The global score ranges from 0 to 21; a normal cut of value of 5 was used. A score of \>5 was used to indicate significant sleep disturbance, with higher scores indicating higher levels of sleep disturbance. It was reported that this score had a diagnostic sensitivity of 89.6% and specificity of 86.5% in differentiating poor from good sleepers.[@CIT0011]

### Epworth Sleepiness Scale (ESS) {#S0002-S2003-S3003}

The ESS is a validated reliable self-administered questionnaire used to assess subjective daytime sleepiness.[@CIT0012] A subject with a score \>10 is considered to have excessive daytime sleepiness (EDS).

### Berlin questionnaire {#S0002-S2003-S3004}

The Berlin questionnaire is a widely used reliable questionnaire.[@CIT0013] This tool was originally designed as a mean for clinicians to quickly establish apnea risk factors and has been validated in patients aged 18 years or older. The scoring process includes evaluating "yes or no" responses and multiple-choice selections and includes space for calculating the BMI based on the respondent's measurements. Points are assigned to responses indicating more acute symptoms. For "yes or no" questions, one point is given for each "yes" answer. In the case of the multiple-choice questions, the two answers that correspond to the highest severity of apnea both receive one point. Categories one and two are considered high risk if the individual receives two or more points. The respondent is considered high risk in category three (obesity and blood pressure) if their blood pressure is high or their BMI is \>30 kg/m^2^.

### Athens Insomnia Scale (AIS) {#S0002-S2003-S3005}

The AIS is a validated scale used to assess the severity of insomnia using diagnostic criteria set forth by the International Classification of Diseases (ICD-10).[@CIT0014] This eight-item questionnaire evaluates sleep onset, night and early-morning waking, sleep time, sleep quality, frequency and duration of complaints, distress caused by the experience of insomnia, and interference with daily functioning.

### International RLS Study Group (IRLSSG) {#S0002-S2003-S3006}

The criteria for the diagnosis of RLS were modified in 2014.[@CIT0015] The IRLSSG consists of four "yes/no" questions and is used as a test to screen for RLS. In addition, a fifth criterion for clinically excluding other conditions that may mimic RLS is mandatory to confirm the diagnosis of RLS. All the five criteria must be met to diagnose RLS.

### Health Assessment Questionnaire (HAQ) {#S0002-S2003-S3007}

The HAQ is a patient-oriented questionnaire used to assess the quality of life in different medical fields, such as RA. The HAQ assesses disability, discomfort, medication side effects, costs, and mortality through a questionnaire consisting of 20 questions that assess the upper and lower limbs.[@CIT0016] These questions are organized into the following eight categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each question is answered on a four-level scale of impairment ranging from 0 to 3 as follows: 0=no difficulty; 1=some difficulty; 2=much difficulty; and 3=inability to perform the activity. The final result is calculated by summing all categories.

Statistical analysis {#S0002-S2004}
--------------------

The means and standard deviations of the continuous demographic and baseline characteristics and laboratory tests of the participants \[age, BMI, RA Disease Activity DAS28, CRP, ESR, RF, anti-cyclic citrullinated peptide, serum ferritin, thyroid-stimulating hormone, vitamin B12, urea, creatinine, and hemoglobin A1c (HbA1c)\] are reported. The frequencies and percentages of the categorical characteristics, sleep disorders and risk factors (age classification, gender, smoking status, BMI classification, RA Disease Activity classification DAS28, any comorbidities, hypertension, diabetes, ischemic events, insomnia, EDS, sleep disturbance, sleep apnea, and RLS), are reported.

The association between the RA disease activity and different sleep disorders (insomnia, EDS, sleep disturbance, sleep apnea, and RLS) was tested using a chi-square test. The association between the risk factors and sleep disorders in the RA patients was tested using a chi-square test, Fisher's exact test or Student's *t*-test. The association between the HAQ and sleep disorders was tested using a Student's *t*-test. The significance level was set at *P*\<0.05, and all statistical analyses were conducted using STATA Version 13.0 (StataCorp, College Station, TX, USA).

Results {#S0003}
=======

The demographic and baseline characteristics of the 101 participants included in the study are presented in [Table 1](#T0001){ref-type="table"}. The mean age of the participants was 48.7±14.6 years. Approximately 95% and 97% of the participants were female and never smoked, respectively. The mean BMI was 32.1±10.2 kg/m^2^; more than half of the participants were classified as obese, and approximately 30% of the participants were classified as overweight. Approximately 60% of the participants were in the remission/low category of disease activity, and the average RA Disease Activity Score (DAS28) was 3.3±0.8 years. Regarding comorbidities, approximately half of the participants had at least one comorbidity. The mean values of the laboratory blood tests are illustrated in [Table 1](#T0001){ref-type="table"}.Table 1Characteristics of the study populationCharacteristicsn%Age, years (mean±SD)48.7±14.6Gender Female9695 Male55Smoking status Ever33 Never9897RA disease activity Remission/low6059 Moderate/high4141RA disease duration (mean±SD, years)7.8±6.6BMI (mean±SD, kg/m^2^)32.1±10.2BMI classification Underweight/normal2020 Overweight2727 Obese5454Hemoglobin (mean±SD, g/dL)13.4±11.3Serum ferritin (mean±SD, μg/L)37.6±40.5Iron (mean±SD, μmol/L)12.7±14.8TSH (mean±SD, U/mL)3.2±5.4**ComorbiditiesN%**Any comorbidity3939Hypertension2525Diabetes2121Stroke22Ischemic heart disease33Gastroesophageal reflux disease77Chronic obstructive pulmonary disease11[^1]

The prevalence of insomnia, EDS, sleep disturbance, sleep apnea, and RLS among the participants was 63%, 20%, 20%, 37%, and 63%, respectively. Furthermore, the distribution of insomnia, EDS, sleep disturbance, sleep apnea, and RLS according to the RA Disease Activity was similar between the patients with remission/low disease activity and those with moderate/high disease activity and showed no significant differences ([Table 2](#T0002){ref-type="table"}).Table 2Insomnia, EDS, sleep apnea, sleep disturbance and RLS according to RA disease activitySleep disorderTotalDisease activity (DAS28)*P*-valueRemission/lowModerate/highN%n%n%**Insomnia (AIS)** Yes6463396525610.680 No373721351639**EDS (ESS)** Yes (\>/=10)202012208200.952 No (\<10)818048803380**Sleep disturbance (PSQI)** Yes (a score of \>5)202012208200.886 No (a score of ≤5)798046793380**Sleep apnea (Berlin Score)** High risk3737193218440.210 Low risk646341682356**RLS (IRLSSG criteria)** Yes6463386326630.993 No373722371537[^2]

The associations between the different risk factors and insomnia, sleep disturbance, EDS, RLS, and sleep apnea are summarized in [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"}. However, insomnia showed no association with any of the suggested risk factors except for gender (*P*=0.039) ([Table 3](#T0003){ref-type="table"}). Age, BMI classification, any comorbidity, hypertension, and diabetes showed significant associations with sleep apnea. Additionally, 49% of the participants with any comorbidity were categorized as high risk for sleep apnea, while only 25% of those with no comorbidity were categorized as high risk (*P*=0.012). The high-risk group had increased percentages of hypertension and diabetes (*P*≤0.001, 0.001, respectively) ([Table 4](#T0004){ref-type="table"}). The associations between the different risk factors and RLS in the RA patients were non-significant except for serum ferritin level ([Table 4](#T0004){ref-type="table"}). A lower level of serum ferritin was detected in patients who met the IRLSSG criteria (*P*=0.022). Finally, the association between HAQ and sleep disorders among the RA patients was non-significant ([Table 5](#T0005){ref-type="table"}).Table 3Risk factors for insomnia; sleep disturbance and excessive daytime sleepiness among RA patientsVariableInsomnia\
(AIS)*P*-ValueSleep disturbance (PSQI)*P*-valueEDS\
(ESS)*P*-valuen (%)n (%)n (%)YesNoYesNoYesNoAge, years (mean±SD)48±1450±160.45348 (15)51 (13)0.56849 (15)47 (15)0.600**Gender** Female63 (66)33 (34)**0.039**74 (79)20 (21)0.24876 (79)20 (21)0.254 Male1 (20)4 (80)5 (100)0 (0)5 (100)0 (0)**BMI (mean**±**SD, kg/m^2^)**32±1031±90.50132 (10)33 (11)0.57531 (10)33 (11)0.735**BMI classification** Underweight/normal13 (65)7 (35)0.33616 (84)3 (16)0.79016 (80)4 (20)0.733 Overweight14 (52)13 (48)22 (81)5 (19)23 (85)4 (15) Obese36 (68)17 (32)41 (77)12 (23)42 (78)12 (22)**Hemoglobin (g/dL)**14 (14)12 (2)0.59514 (13)12 (1)0.56212 (2)18 (25)0.535**Serum ferritin (μg/L)**34 (34)44 (51)0.26037 (34)42 (61)0.57836 (40)45 (43)0.350**Iron (μmol/L)**12 (9)14 (22)0.46613 (16)10 (5)0.34112 (8)16 (29)0.227**TSH (U/mL)**3 (6)3 (5)0.8042 (2)6 (11)0.0033 (6)2 (1)0.439**Any comorbidity**26 (67)13 (33)0.58530 (77)9 (23)0.56632 (82)7 (18)0.711**Hypertension**17 (68)8 (32)0.55018 (72)7 (28)0.26119 (76)6 (24)0.564**Diabetes**16 (76)5 (24)0.15918 (86)3 (14)0.44716 (76)5 (24)0.623**Stroke**1 (50)1 (50)0.6852 (100)0 (0)0.4832 (100)0 (0)0.472**Ischemic heart disease**2 (67)1 (33)0.9123 (100)0 (0)0.3882 (67)1 (33)0.565**GERD**3 (43)4 (57)0.2366 (86)1 (14)0.7236 (86)1 (14)0.686**COPD**1 (100)0 (0)0.4471 (100)0 (0)0.6221 (100)0 (0)0.613[^3] Table 4Risk factors for sleep apnea and RLS among RA patientsVariableSleep Apnea\
(Berlin Score)*P*-valueRLS\
(IRLSSG criteria)*P*-ValueHigh riskLow riskYesNoAge, years (mean±SD)53 (12)46 (15)**0.016**48 (14)49 (16)0.896Gender Female35 (37)60 (63)0.87360 (63)35 (37)0.873 Male2 (40)3 (60)3 (60)2 (40)BMI (mean±SD, kg/m2)34 (9)30 (11)0.13532 (11)32 (9)0.694BMI Classification Underweight/normal2 (10)18 (90)**0.022**13 (65)7 (35)0.611 Overweight12 (44)15 (56)19 (70)8 (30) Obese23 (43)30 (57)31 (58)22 (42)Hemoglobin (g/dL)12 (2)14 (14)0.44214 (14)12 (1)0.497Serum ferritin (μg/L)34 (24)40 (48)0.45131 (24)50 (58)**0.022**Iron (μmol/L)11 (6)13 (18)0.46613 (18)11 (7)0.632TSH (U/mL)2 (1)4 (7)0.2162 (2)5 (8)0.520Any comorbidity22 (56)17 (44)**0.001**21 (54)18 (46)0.115Hypertension19 (76)6 (24)**0.000**15 (60)10 (40)0.720Diabetes14 (67)7 (33)**0.001**10 (48)11 (52)0.100Stroke1 (50)1 (50)0.6622 (100)0 (0)0.270Ischemic heart disease0 (0)3 (100)0.1932 (67)1 (33)0.883GERD0 (0)7 (100)0.0423 (43)4 (57)0.262COPD0 (0)1 (100)0.4571 (100)0 (0)0.437[^4] Table 5Association between the HAQ and sleep disorders in RA patientsSleep DisorderHAQ (n=75)*P*-valueMeanSDInsomnia (AIS) Yes1.000.470.244 No0.910.42EDS (ESS) Yes (\>/=10)1.080.440.404 No (\<10)0.980.52Sleep disturbance (PSQI) Yes (a score of \>5)1.000.440.529 No (a score of ≤5)0.920.38Sleep apnea (Berlin Score) High risk1.060.460.354 Low risk0.960.46RLS (IRLSSG criteria) Yes1.010.470.864 No0.990.44[^5]

Discussion {#S0004}
==========

This study showed that sleep disorders are actually common among patients with RA. Insomnia and RLS were the most common sleep disorders, both of which affected 63% of the study population. Furthermore, a high risk of OSA was reported in 37% of the subjects, while poor sleep quality and EDS affected one-fifth of the study population. Moreover, sleep disorders in conjunction with severe RA had no effect on the quality of life.

In this study, the prevalence of RLS in the RA patients (63%) was much higher than that in the general Saudi population (8.4%).[@CIT0017] This higher prevalence can be explained by the high risk of iron deficiency anemia secondary to the chronic use of NSAIDs in the RA patients,[@CIT0018] which was identified as the main risk factor for secondary RLS.[@CIT0019] Iron deficiency was further confirmed in our study population by the presence of low serum ferritin in patients with RLS. In addition, the prevalence of RLS reported in this study was higher than that reported among RA patients in other studies. Reynolds et al[@CIT0020] reported a strong link between RLS and RA disease with a prevalence of 5--15%; however, the previous study did not use the standard IRLSSG criteria. This discrepancy was explained by iron deficiency anemia and chronic inflammatory conditions with the secretion of multiple cytokines and inflammatory mediators.[@CIT0021],[@CIT0022] Taylor-Gjevre et al[@CIT0022] used the standard IRLSSG criteria to screen RA patients and found that approximately a quarter of RA patients had RLS significantly affecting their quality of life. However, most patients with RLS were underdiagnosed due to the lack of awareness of health care professionals.[@CIT0004]

The risk of insomnia based on AIS in the Saudi population is approximately 77%.[@CIT0023] This study showed that two-thirds of the study population had insomnia, which is close to that reported in the general population. Furthermore, this percentage is higher than the globally reported percentage among RA patients. Freitas et al[@CIT0003] used the Nottingham Health Profile and revealed that 55% of rheumatoid patients suffered from insomnia. This finding was explained by pain, functional disability, and depression. Moreover, Westhovens et al[@CIT0001] confirmed the positive relationship between active RA and insomnia by using the AIS. These results were explained by the presence of attentiveness secondary to pain.

The relationship between RA and OSA has been reported in several studies conducted worldwide. Reading et al[@CIT0002] showed that half of the rheumatoid patients have OSA. Furthermore, Sugahara et al[@CIT0024] demonstrated a high risk of OSA (75%) in RA patients compared to that in non-RA subjects. In our study, a high risk of OSA was found in 37% of patients, which is much higher than the estimated prevalence of clinically significant OSA in a sample of the Saudi population (8.5%; 12.4% in men and 4.8% in women).[@CIT0025] Furthermore, we found that the association between high disease activity and sleep apnea was not statistically significant. A larger sample size may be needed to identify a significant association. However, aging, diabetes, hypertension, and obesity were found to be significant risk factors for OSA, which is consistent with the reported literature.[@CIT0025] Furthermore, acquired retrognathia secondary to TMJdestruction in RA has been proposed as a risk factor for OSA and probably attributes to the high risk of OSA in RA.[@CIT0026] Hence, the risk of OSA is particularly high in patients with RA, and our study population had predisposing factors similar to those previously reported despite the limited data.

EDS is strongly related to the female gender and has been observed in 20% of the general population,[@CIT0027] which is comparable to our finding that 20% of our study population had EDS. Moreover, this value is similar to that reported in the literature. Abbasi et al[@CIT0005] showed that 24% of rheumatoid patients complain of EDS.

Poor sleep quality affects 20% of RA patients regardless of disease activity, which may be due to the effect of pain in active RA that can lead to frequent awakening episodes as shown in a previous study.[@CIT0001] To the best of our knowledge, no local data addressing the prevalence of sleep disturbances among Saudis are available. However, Abbasi et al[@CIT0005] showed decreased sleep quality in three-quarters of RA patients due to the presence of pain.

Despite the known detrimental effect of sleep disorders on the quality of life, we did not observe a significant relationship between these disorders and the quality of life in the RA patients. This discrepancy could be explained by the fact that RA patients already have a lower standard quality of life, and sleep disorders do not substantially decrease their quality of life. Another explanation for this nonsignificant result could be related to the distribution of our patient population. Most RA patients recruited in this study were in the remission/low-risk group.

The strengths of our study include a study population representative of patients with a confirmed diagnosis of RA based on validated criteria (ARA 1987).[@CIT0014] Furthermore, although RA is an uncommon disease, a reasonable sample size of 101 patients was included. In addition, the distribution of disease activity was approximately even, and low and high disease activity represented 60% and 40% of the patients, respectively. However, this study has several limitations. First, this study adopted a cross-sectional design. Second, a confirmatory test using polysomnography to diagnose OSA was not used. Third, we did not include a control group for comparison. Finally, information regarding medications, which may play a role in sleep disorders, was not collected in our study.

Conclusion {#S0005}
==========

Sleep disorders are common among RA patients and may require further attention by treating clinicians. This study showed no association between sleep disorders and the quality of life in RA patients, but this association could be masked by the lower quality of life experienced by RA patients due to pain and activity levels.
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AIS, Athens Insomnia Scale; ARA, American Rheumatology Association; BMI, body mass index; CBCs, complete blood counts; CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score; EDS, excessive daytime sleepiness; ESR, erythrocyte sedimentation rate; ESS, Epworth Sleepiness Scale; HAQ, Health Assessment Questionnaire; HbA1c, hemoglobin A1c; ICD-10, International Classification of Diseases; IRLSSG, International RLS Study Group; KAUH, King Abdulaziz University Hospital; MCP, metacarpophalangeal joints; OSA, obstructive sleep apnea; PIP, proximal interphalangeal joints; RA, rheumatoid arthritis; RF, rheumatoid factor; RLS, restless legs syndrome; TMJ, temporomandibular joint; TSH, thyroid-stimulating hormone.
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